The Oral GLP-1 Frontier: Phase II Trial Shows Aleniglipron Delivers Up to 12% Weight Loss in Adults with Obesity
Executive Overview The landscape of obesity pharmacotherapy is undergoing a seismic shift. For years, the gold standard in incretin-based therapeutics has relied heavily on injectable peptide formulations—compounds that, while clinically…